Polyphor achieves first milestone in collaboration with Boehringer02.08.2013 09:23
Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, today announced that Boehringer Ingelheim has decided to enter into the next stage of its drug discovery collaboration with Polyphor. Financial details were not disclosed.
This collaborative project was originally initiated in June 2012 with the objective to discover and develop novel macrocyclic compounds for targets nominated by Boehringer Ingelheim. Following the successful hit identification phase, the parties have now agreed to move forward to generate candidates suitable for pre-clinical development.
Daniel Obrecht, co-founder and CSO of Polyphor, commented: „We are extremely pleased to move this collaboration with Boehringer Ingelheim to the next research stage. This achievement clearly demonstrates that our proprietary MacroFinder platform can successfully address difficult intracellular targets where small molecule approaches have failed so far. We look forward to extending and further strengthening the collaboration with our research partners at Boehringer Ingelheim.”
In June 2012 Polyphor entered into a multi-year, multi-target drug discovery alliance with Boehringer Ingelheim in which Polyphor is applying its proprietary MacroFinder drug discovery technology to identify and optimize novel macrocyclic drug candidates addressing challenging therapeutic targets selected by Boehringer Ingelheim. Boehringer Ingelheim will then be solely responsible for subsequent development and commercialization of the identified drug candidates. In return, Polyphor receives an up-front payment, research funding, milestone payments and royalties on the commercial sales of any approved products.